We conducted a prospective study in hemodialyzed patients of our department to evaluate the incidence of seroconversion for HCV in this high-risk group; 165 patients were seronegative and 53 seropositive for anti-HCV antibodies at the start of this study. During the average follow-up period of 27.8 months, one patient developed anti-HCV antibodies late in the study, while the other 154 patients remained seronegative through the follow-up. Our results show a very low incidence of HCV-seropositivity (0.26% per year) after implementation of our operative protocol including 'universal precautions' and other infection control procedures. Once infected, there is no disappearance rate of anti-HCV. The 4-RIBA results did not change during the follow-up period. HCV-RNA was detected in 4 of 27 anti-HCV positive patients tested by a RT-PCR which uses primers from the 5' non coding region (5' NCR) of the HCV genoma. The exact route of transmission of HCV among HD patients needs future investigation; long-term prospective studies are necessary to confirm these results.
|Translated title of the contribution||Incidence of seroconversion for hepatitis C virus (HCV) in chronic hemodialysis (HD) patients: A prospective study|
|Number of pages||7|
|Journal||Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia|
|Publication status||Published - 1994|
ASJC Scopus subject areas